Review



5 fluorouracil 5fu  (Sandoz)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 86
      Buy from Supplier

    Structured Review

    Sandoz 5 fluorouracil 5fu
    5 Fluorouracil 5fu, supplied by Sandoz, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/5+5fu+fluorouracil/pmc12817082-61-0-2
    Average 86 stars, based on 1 article reviews
    5 fluorouracil 5fu - by Bioz Stars, 2026-10
    86/100 stars

    Images

    Related Articles

    Injection:

    Article Title: Mbd4 and MutSα protect cells from spontaneous deamination of 5-methylcytosine
    Article Snippet: .. 5-fluorouracil (5FU) (Sandoz) was diluted in PBS and mice were injected intravenously once with 150 mg/kg. ..



    Similar Products

    long term 5 fu  (InvivoGen)
    94
    InvivoGen long term 5 fu
    Long Term 5 Fu, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/5-Fluorouracil/pm41931852-49-4-6
    Average 94 stars, based on 1 article reviews
    long term 5 fu - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    5 fluorouracil 5fu  (Sandoz)
    86
    Sandoz 5 fluorouracil 5fu
    5 Fluorouracil 5fu, supplied by Sandoz, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/5+5fu+fluorouracil/pmc12817082-61-0-2
    Average 86 stars, based on 1 article reviews
    5 fluorouracil 5fu - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    clinical grade 5 fluorouracil 5fu  (Fresenius Kabi)
    86
    Fresenius Kabi clinical grade 5 fluorouracil 5fu
    Clinical Grade 5 Fluorouracil 5fu, supplied by Fresenius Kabi, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/5+5fu+clinical+fluorouracil+grade/10__1093_slash_narmme_slash_ugag005-60-0-19
    Average 86 stars, based on 1 article reviews
    clinical grade 5 fluorouracil 5fu - by Bioz Stars, 2026-10
    86/100 stars
    		  Buy from Supplier
    5 fluorouracil 5fu  (MedChemExpress)
    98
    MedChemExpress 5 fluorouracil 5fu
    5 Fluorouracil 5fu, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/5-Fluorouracil/pm40615893-78-52-56
    Average 98 stars, based on 1 article reviews
    5 fluorouracil 5fu - by Bioz Stars, 2026-10
    98/100 stars
    		  Buy from Supplier
    recombinant proteins 5 fluorouracil 5fu selleckchem  (Selleck Chemicals)
    96
    Selleck Chemicals recombinant proteins 5 fluorouracil 5fu selleckchem
    Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or cisplatin (CDDP) at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil <t>(5FU),</t> 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).
    Recombinant Proteins 5 Fluorouracil 5fu Selleckchem, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/Fluorouracil/pm40513578-256-147-151
    Average 96 stars, based on 1 article reviews
    recombinant proteins 5 fluorouracil 5fu selleckchem - by Bioz Stars, 2026-10
    96/100 stars
    		  Buy from Supplier
    fluorouracil  (InvivoGen)
    94
    InvivoGen fluorouracil
    Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or cisplatin (CDDP) at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil <t>(5FU),</t> 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).
    Fluorouracil, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/5-Fluorouracil/pmc11614707-42-0-4
    Average 94 stars, based on 1 article reviews
    fluorouracil - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    5 fu  (InvivoGen)
    94
    InvivoGen 5 fu
    Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or cisplatin (CDDP) at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil <t>(5FU),</t> 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).
    5 Fu, supplied by InvivoGen, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/5-Fluorouracil/us12295973-913-0-1
    Average 94 stars, based on 1 article reviews
    5 fu - by Bioz Stars, 2026-10
    94/100 stars
    		  Buy from Supplier
    fluorouracil 5fu  (MedChemExpress)
    98
    MedChemExpress fluorouracil 5fu
    Cultivation of HCC-laden DHCM/GelMA microgels. (A) Optical observation of HCC-laden DHCM/GelMA microgels following 7 days of in vitro culture. (B) DNA quantification of HCC-laden DHCM/GelMA microgels after 7 days of in vitro culture. (C) Observations of HCCs cultured in DHCM/GelMA microgels under graded concentrations of 5-fluorouracil <t>(5FU),</t> with quantitative analysis of live/dead staining results. (D) Viability analysis and proliferation curve of HCCs embedded in DHCM/GelMA microgels during 1 week of in vitro culture under 5FU treatment.
    Fluorouracil 5fu, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/5-Fluorouracil/pmc11949893-53-0-5
    Average 98 stars, based on 1 article reviews
    fluorouracil 5fu - by Bioz Stars, 2026-10
    98/100 stars
    		  Buy from Supplier
    5-fluorouracil (5fu)  (Kyowa Hakko Kirin Korea Co Ltd)
    90
    Kyowa Hakko Kirin Korea Co Ltd 5-fluorouracil (5fu)
    84-EBET shows substantial anticancer efficacy in CRC, LC, and BC models in vitro and in vivo . A, IHC analysis of CRC-1, CRC-5, BRE-704, and H1573 tumors. Scale bar, 100 μm. B, Growth inhibition by ADCs and standard chemotherapies in CRC-1, CRC-5, and BRE-704 PDX-derived organoids and the H1573 cell line. Data are presented as mean ± SD ( n = 4 biological replicates). Fitted curves with nonlinear regression are shown. SN38, an active metabolite of irinotecan. <t>5FU</t> + OXA has a different concentration range (10 nmol/L to 100 µmol/L + 1 nmol/L to 10 µmol/L) from those of the other agents. C, Relative tumor growth curves in response to ADCs and standard chemotherapies in CRC-1, CRC-5, BRE-704, and H1573 xenograft models. Arrowheads indicate times of drug administration. Data are presented as mean ± SD ( n = 5 mice). CDX, cell line–derived xenograft; HEL, hen-egg lysozyme 3 (control).
    5 Fluorouracil (5fu), supplied by Kyowa Hakko Kirin Korea Co Ltd, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/5+fluorouracil+5fu/5+fluorouracil/pmc11876960-41-14-17
    Average 90 stars, based on 1 article reviews
    5-fluorouracil (5fu) - by Bioz Stars, 2026-10
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or cisplatin (CDDP) at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil (5FU), 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).

    Journal: Cancer cell

    Article Title: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

    doi: 10.1016/j.ccell.2025.05.014

    Figure Lengend Snippet: Figure 1. Schematic representation of the experimental workflow Syngeneic murine colorectal cancer (CRC) and breast cancer cells were treated with temozolo- mide (TMZ) and/or cisplatin (CDDP) at clinically relevant concentrations in a pulsatile schedule (2 days treatment followed by drug washout and cell passaging) for a total of 12 in vitro treatment cycles (priming phase). Drug concentrations were as follows: 25 μM for TMZ and 1.5 μM for CDDP. Additionally, CRC cells were also treated with the standard-of-care cytotoxic agents: 2 μM for 5-fluorouracil (5FU), 5 μM for oxaliplatin (Oxa), and 35 nM for SN38 (the main active metabolite of iri- notecan). Primed cells were kept in drug-free medium for two passages and then injected into immunodeficient and immunocompetent mice to study the extent of immunological control induced by treatment with chemotherapeutic agents (ed- iting phase). Whole exome sequencing (WES) was performed at baseline (T0), at the end of the in vitro priming phase (T1) and on established tumors at the end of the in vivo challenge phase (T2).

    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Alexa Fluor 647 Rat anti-mouse Perforin (clone S16009A) Biolegend Cat# 154307; RRID:AB_2922480 Rabbit Recombinant Monoclonal anti-MLH1 (EPR3894) Abcam Cat# ab92312; RRID:AB_2049968 Rabbit Recombinant Monoclonal anti-MSH6 antibody (EPR3945) Abcam Cat# ab92471; RRID:AB_2144959 Rabbit Polyclonal anti-MSH2 Abcam Cat# ab70270; RRID:AB_1269470 Mouse Monoclonal Antibody anti-PMS2 (163C1251) Thermo Fisher Cat# MA1-41245; RRID:AB_2284116 Mouse Monoclonal Antibody anti-MGMT (MT3.1) Thermo Fisher Cat# MA5-13506; RRID:AB_10982210 Polyclonal anti-beta Actin (I-19) Santa Cruz Biotechnology Cat# Sc-1616 RRID:AB_630836 Mouse Monoclonal Antibody anti-MSH6 BioCare Cat# CM265AK; RRID:AB_10583038 Mouse Monoclonal Antibody anti-MSH2 BioCare Cat# CM 219 AK; RRID:AB_10582728 Rabbit monoclonal antibody anti-mouse CD8a (EPR21769) Abcam Cat# ab217344; RRID:AB_2890649 Rabbit monoclonal antibody anti-mouse CD4 (EPR19514) Abcam Cat# ab183685; RRID:AB_2686917 Rabbit monoclonal antibody anti-mouse FoxP3 (D6O8R) Cell Signaling Technology Cat# 12653 InVivoPlus anti-mouse PD-1 (CD279) BioxCell Cat# BP0146 RRID:AB_10949053 InVivoPlus anti-mouse CD4 BioxCell Cat# BP0003-1 RRID:AB_1107636 InVivoPlus anti-mouse CD8α BioxCell Cat# BP0117 RRID:AB_10950145 Chemicals, peptides, and recombinant proteins 5-fluorouracil (5FU) Selleckchem Cat# S1209 Oxaliplatin (Oxa) Selleckchem Cat# S1224 SN38 Selleckchem Cat# S4908 Temozolomide (TMZ) Selleckchem Cat# S1237 Cisplatin (CDDP) Selleckchem Cat# S1166 Irinotecan hydrochloride MedChem Express Cat# HY-16562A Decitabine (DAC) Selleckchem Cat#S1200 Critical commercial assays CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 FoxP3/Transcription factor staining buffer Set eBioscence Invitrogen Cat# 00-5523-00 Tumor dissociation Kit Miltenyi Biotec Cat# 130-096-730 Cell blox plus blocking buffer Invitrogen Bioscience Cat# C001T02F01 Maxwell RSC simplyRNA tissue system Promega Cat# AS1340 Relia Prep gDNA tissue miniprep system Promega Cat# A2051 Brilliant Stain Buffer Plus BD Horizon Cat# 566385 Fixable viability stain 700 BD Horizon Cat# 564997 Peroxidase substrate kit Vector lab Cat# SK-4100 BCA Protein Assay Reagent Kit Thermo Scientific Cat# 23235 Deposited data Whole exome and RNA sequencing data European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena/ browser/view/PRJEB77057 (Continued on next page) Cancer Cell 43, 1–17.e1–e7, July 14, 2025 e2

    Techniques: Passaging, In Vitro, Injection, Control, Sequencing, In Vivo

    Figure 6. Two cycles of in vivo chemotherapy induce a remodeling of the tumor immune microenvironment (A) Experimental workflow: a total of 5 × 10 5 chemotherapy-naive CT26 cells were injected into the flank of immunocompetent mice. On day 6, when the average tumor volume was 60–100 mm 3 , mice were randomized into 5 treatment groups: CTRL (saline vehicle), TMZ (20 mg/kg day-1-5 weekly), CDDP (5 mg/kg day 1 weekly), TMZ + CDDP, and FOLFOXIRI (5FU 25 mg/kg day 1, oxaliplatin 3 mg/kg day 1, irinotecan 25 mg/kg day 1, weekly). After two weeks of treatment, tumors were harvested, dissociated into single cell suspensions, and immunostained for flow cytometry analysis. Each tumor suspension was analyzed using spectral flow cytometry and results were elaborated using an unbiased bioinformatic pipeline (see STAR Methods). (B) Average tumor volume ± SEM of tumors treated with chemotherapy in vivo. The vertical red dotted line indicates day 1 of each chemotherapy cycle. Statistical significance evaluated by Mann-Whitney test; ns, not significant (p ≥ 0.05); *p < 0.05. (C) Relative average distribution of the 23 immune clusters across the treatment arms. (D–J) Distribution of relevant immune populations across the different experimental arms. Boxplots represent the median value (horizontal bar), the interquartile range (box) and the minimum and maximum values (whiskers) of the percentage of the specific cluster in each analyzed tumor (n = 10 tumors/condition). (D) Distribution of total NK cells over CD45 + cells (clusters 7–9); (E) cytotoxic NK cells over CD45 + cells (perforin positive, clusters 7 and 9); (F) relative abundance of

    Journal: Cancer cell

    Article Title: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

    doi: 10.1016/j.ccell.2025.05.014

    Figure Lengend Snippet: Figure 6. Two cycles of in vivo chemotherapy induce a remodeling of the tumor immune microenvironment (A) Experimental workflow: a total of 5 × 10 5 chemotherapy-naive CT26 cells were injected into the flank of immunocompetent mice. On day 6, when the average tumor volume was 60–100 mm 3 , mice were randomized into 5 treatment groups: CTRL (saline vehicle), TMZ (20 mg/kg day-1-5 weekly), CDDP (5 mg/kg day 1 weekly), TMZ + CDDP, and FOLFOXIRI (5FU 25 mg/kg day 1, oxaliplatin 3 mg/kg day 1, irinotecan 25 mg/kg day 1, weekly). After two weeks of treatment, tumors were harvested, dissociated into single cell suspensions, and immunostained for flow cytometry analysis. Each tumor suspension was analyzed using spectral flow cytometry and results were elaborated using an unbiased bioinformatic pipeline (see STAR Methods). (B) Average tumor volume ± SEM of tumors treated with chemotherapy in vivo. The vertical red dotted line indicates day 1 of each chemotherapy cycle. Statistical significance evaluated by Mann-Whitney test; ns, not significant (p ≥ 0.05); *p < 0.05. (C) Relative average distribution of the 23 immune clusters across the treatment arms. (D–J) Distribution of relevant immune populations across the different experimental arms. Boxplots represent the median value (horizontal bar), the interquartile range (box) and the minimum and maximum values (whiskers) of the percentage of the specific cluster in each analyzed tumor (n = 10 tumors/condition). (D) Distribution of total NK cells over CD45 + cells (clusters 7–9); (E) cytotoxic NK cells over CD45 + cells (perforin positive, clusters 7 and 9); (F) relative abundance of

    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Alexa Fluor 647 Rat anti-mouse Perforin (clone S16009A) Biolegend Cat# 154307; RRID:AB_2922480 Rabbit Recombinant Monoclonal anti-MLH1 (EPR3894) Abcam Cat# ab92312; RRID:AB_2049968 Rabbit Recombinant Monoclonal anti-MSH6 antibody (EPR3945) Abcam Cat# ab92471; RRID:AB_2144959 Rabbit Polyclonal anti-MSH2 Abcam Cat# ab70270; RRID:AB_1269470 Mouse Monoclonal Antibody anti-PMS2 (163C1251) Thermo Fisher Cat# MA1-41245; RRID:AB_2284116 Mouse Monoclonal Antibody anti-MGMT (MT3.1) Thermo Fisher Cat# MA5-13506; RRID:AB_10982210 Polyclonal anti-beta Actin (I-19) Santa Cruz Biotechnology Cat# Sc-1616 RRID:AB_630836 Mouse Monoclonal Antibody anti-MSH6 BioCare Cat# CM265AK; RRID:AB_10583038 Mouse Monoclonal Antibody anti-MSH2 BioCare Cat# CM 219 AK; RRID:AB_10582728 Rabbit monoclonal antibody anti-mouse CD8a (EPR21769) Abcam Cat# ab217344; RRID:AB_2890649 Rabbit monoclonal antibody anti-mouse CD4 (EPR19514) Abcam Cat# ab183685; RRID:AB_2686917 Rabbit monoclonal antibody anti-mouse FoxP3 (D6O8R) Cell Signaling Technology Cat# 12653 InVivoPlus anti-mouse PD-1 (CD279) BioxCell Cat# BP0146 RRID:AB_10949053 InVivoPlus anti-mouse CD4 BioxCell Cat# BP0003-1 RRID:AB_1107636 InVivoPlus anti-mouse CD8α BioxCell Cat# BP0117 RRID:AB_10950145 Chemicals, peptides, and recombinant proteins 5-fluorouracil (5FU) Selleckchem Cat# S1209 Oxaliplatin (Oxa) Selleckchem Cat# S1224 SN38 Selleckchem Cat# S4908 Temozolomide (TMZ) Selleckchem Cat# S1237 Cisplatin (CDDP) Selleckchem Cat# S1166 Irinotecan hydrochloride MedChem Express Cat# HY-16562A Decitabine (DAC) Selleckchem Cat#S1200 Critical commercial assays CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 FoxP3/Transcription factor staining buffer Set eBioscence Invitrogen Cat# 00-5523-00 Tumor dissociation Kit Miltenyi Biotec Cat# 130-096-730 Cell blox plus blocking buffer Invitrogen Bioscience Cat# C001T02F01 Maxwell RSC simplyRNA tissue system Promega Cat# AS1340 Relia Prep gDNA tissue miniprep system Promega Cat# A2051 Brilliant Stain Buffer Plus BD Horizon Cat# 566385 Fixable viability stain 700 BD Horizon Cat# 564997 Peroxidase substrate kit Vector lab Cat# SK-4100 BCA Protein Assay Reagent Kit Thermo Scientific Cat# 23235 Deposited data Whole exome and RNA sequencing data European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena/ browser/view/PRJEB77057 (Continued on next page) Cancer Cell 43, 1–17.e1–e7, July 14, 2025 e2

    Techniques: In Vivo, Injection, Saline, Flow Cytometry, Suspension, MANN-WHITNEY

    Figure 7. In vivo concomitant treatment with CDDP and TMZ is immunogenic and induces complete regressions in combination with anti- PD-1 (A) Graphical summary: a total of 5 × 10 5 chemotherapy-naive CT26 cells were injected in the flank of immunocompetent mice until establishment of measurable tumors (average volume >50 mm 3 ). After that, mice were randomized in 4 groups: vehicle (CTRL), anti-PD-1 (aPD-1), chemotherapy (CDDP+TMZ), and immunotherapy + chemotherapy (aPD-1+CDDP+TMZ). (B and C) Tumor growth of naive CT26-derived tumors treated in vivo with aPD-1, chemotherapy (CDDP+TMZ), or their combination (aPD-1+CDDP+TMZ). (B) Average of tumor volumes (mm 3 ) ± SEM. (C) Individual tumor volumes. CDDP was administered intraperitoneally (i.p.) at 5 mg/kg once a week (vertical red dotted line), TMZ was administered i.p. for 5 consecutive days a week at 20 mg/kg, starting the same day as CDDP (vertical red dotted line) for a total of 2 weeks. Anti- PD-1 was administered i.p. every 2 other days at 250 μg/mouse for a total of 4 doses (vertical black dashed line). (D and E) Tumor growth of naive CT26-derived tumors treated in vivo with chemotherapy (FOLFOXIRI), or its combination with aPD-1 (aPD-1+FOLFOXIRI). (D) Average of tumor volumes (mm 3 ) ± SEM. (E) Individual tumor volumes. Chemotherapy (5FU 25 mg/kg, Oxa 3 mg/kg, irinotecan 25 mg/kg) was administered i.p. once a week once a week (vertical red dotted line) for a total of 2 weeks, anti-PD-1 was administered i.p. every 2 other days at 250 μg/mouse for a total of 4 doses (vertical black dashed line). Statistical significance was evaluated by Mann-Whitney test (B and D); ns, not significant (p ≥ 0.05); * p < 0.05; and **p < 0.01. Each experimental group included at least 6 animals. See also Figure S8.

    Journal: Cancer cell

    Article Title: Cisplatin and temozolomide combinatorial treatment triggers hypermutability and immune surveillance in experimental cancer models.

    doi: 10.1016/j.ccell.2025.05.014

    Figure Lengend Snippet: Figure 7. In vivo concomitant treatment with CDDP and TMZ is immunogenic and induces complete regressions in combination with anti- PD-1 (A) Graphical summary: a total of 5 × 10 5 chemotherapy-naive CT26 cells were injected in the flank of immunocompetent mice until establishment of measurable tumors (average volume >50 mm 3 ). After that, mice were randomized in 4 groups: vehicle (CTRL), anti-PD-1 (aPD-1), chemotherapy (CDDP+TMZ), and immunotherapy + chemotherapy (aPD-1+CDDP+TMZ). (B and C) Tumor growth of naive CT26-derived tumors treated in vivo with aPD-1, chemotherapy (CDDP+TMZ), or their combination (aPD-1+CDDP+TMZ). (B) Average of tumor volumes (mm 3 ) ± SEM. (C) Individual tumor volumes. CDDP was administered intraperitoneally (i.p.) at 5 mg/kg once a week (vertical red dotted line), TMZ was administered i.p. for 5 consecutive days a week at 20 mg/kg, starting the same day as CDDP (vertical red dotted line) for a total of 2 weeks. Anti- PD-1 was administered i.p. every 2 other days at 250 μg/mouse for a total of 4 doses (vertical black dashed line). (D and E) Tumor growth of naive CT26-derived tumors treated in vivo with chemotherapy (FOLFOXIRI), or its combination with aPD-1 (aPD-1+FOLFOXIRI). (D) Average of tumor volumes (mm 3 ) ± SEM. (E) Individual tumor volumes. Chemotherapy (5FU 25 mg/kg, Oxa 3 mg/kg, irinotecan 25 mg/kg) was administered i.p. once a week once a week (vertical red dotted line) for a total of 2 weeks, anti-PD-1 was administered i.p. every 2 other days at 250 μg/mouse for a total of 4 doses (vertical black dashed line). Statistical significance was evaluated by Mann-Whitney test (B and D); ns, not significant (p ≥ 0.05); * p < 0.05; and **p < 0.01. Each experimental group included at least 6 animals. See also Figure S8.

    Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Alexa Fluor 647 Rat anti-mouse Perforin (clone S16009A) Biolegend Cat# 154307; RRID:AB_2922480 Rabbit Recombinant Monoclonal anti-MLH1 (EPR3894) Abcam Cat# ab92312; RRID:AB_2049968 Rabbit Recombinant Monoclonal anti-MSH6 antibody (EPR3945) Abcam Cat# ab92471; RRID:AB_2144959 Rabbit Polyclonal anti-MSH2 Abcam Cat# ab70270; RRID:AB_1269470 Mouse Monoclonal Antibody anti-PMS2 (163C1251) Thermo Fisher Cat# MA1-41245; RRID:AB_2284116 Mouse Monoclonal Antibody anti-MGMT (MT3.1) Thermo Fisher Cat# MA5-13506; RRID:AB_10982210 Polyclonal anti-beta Actin (I-19) Santa Cruz Biotechnology Cat# Sc-1616 RRID:AB_630836 Mouse Monoclonal Antibody anti-MSH6 BioCare Cat# CM265AK; RRID:AB_10583038 Mouse Monoclonal Antibody anti-MSH2 BioCare Cat# CM 219 AK; RRID:AB_10582728 Rabbit monoclonal antibody anti-mouse CD8a (EPR21769) Abcam Cat# ab217344; RRID:AB_2890649 Rabbit monoclonal antibody anti-mouse CD4 (EPR19514) Abcam Cat# ab183685; RRID:AB_2686917 Rabbit monoclonal antibody anti-mouse FoxP3 (D6O8R) Cell Signaling Technology Cat# 12653 InVivoPlus anti-mouse PD-1 (CD279) BioxCell Cat# BP0146 RRID:AB_10949053 InVivoPlus anti-mouse CD4 BioxCell Cat# BP0003-1 RRID:AB_1107636 InVivoPlus anti-mouse CD8α BioxCell Cat# BP0117 RRID:AB_10950145 Chemicals, peptides, and recombinant proteins 5-fluorouracil (5FU) Selleckchem Cat# S1209 Oxaliplatin (Oxa) Selleckchem Cat# S1224 SN38 Selleckchem Cat# S4908 Temozolomide (TMZ) Selleckchem Cat# S1237 Cisplatin (CDDP) Selleckchem Cat# S1166 Irinotecan hydrochloride MedChem Express Cat# HY-16562A Decitabine (DAC) Selleckchem Cat#S1200 Critical commercial assays CellTiter-Glo® Luminescent Cell Viability Assay Promega Cat# G7573 FoxP3/Transcription factor staining buffer Set eBioscence Invitrogen Cat# 00-5523-00 Tumor dissociation Kit Miltenyi Biotec Cat# 130-096-730 Cell blox plus blocking buffer Invitrogen Bioscience Cat# C001T02F01 Maxwell RSC simplyRNA tissue system Promega Cat# AS1340 Relia Prep gDNA tissue miniprep system Promega Cat# A2051 Brilliant Stain Buffer Plus BD Horizon Cat# 566385 Fixable viability stain 700 BD Horizon Cat# 564997 Peroxidase substrate kit Vector lab Cat# SK-4100 BCA Protein Assay Reagent Kit Thermo Scientific Cat# 23235 Deposited data Whole exome and RNA sequencing data European Nucleotide Archive (ENA) https://www.ebi.ac.uk/ena/ browser/view/PRJEB77057 (Continued on next page) Cancer Cell 43, 1–17.e1–e7, July 14, 2025 e2

    Techniques: In Vivo, Injection, Derivative Assay, MANN-WHITNEY

    Cultivation of HCC-laden DHCM/GelMA microgels. (A) Optical observation of HCC-laden DHCM/GelMA microgels following 7 days of in vitro culture. (B) DNA quantification of HCC-laden DHCM/GelMA microgels after 7 days of in vitro culture. (C) Observations of HCCs cultured in DHCM/GelMA microgels under graded concentrations of 5-fluorouracil (5FU), with quantitative analysis of live/dead staining results. (D) Viability analysis and proliferation curve of HCCs embedded in DHCM/GelMA microgels during 1 week of in vitro culture under 5FU treatment.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: A novel approach for engineering DHCM/GelMA microgels: application in hepatocellular carcinoma cell encapsulation and chemoresistance research

    doi: 10.3389/fbioe.2025.1564543

    Figure Lengend Snippet: Cultivation of HCC-laden DHCM/GelMA microgels. (A) Optical observation of HCC-laden DHCM/GelMA microgels following 7 days of in vitro culture. (B) DNA quantification of HCC-laden DHCM/GelMA microgels after 7 days of in vitro culture. (C) Observations of HCCs cultured in DHCM/GelMA microgels under graded concentrations of 5-fluorouracil (5FU), with quantitative analysis of live/dead staining results. (D) Viability analysis and proliferation curve of HCCs embedded in DHCM/GelMA microgels during 1 week of in vitro culture under 5FU treatment.

    Article Snippet: 5-Fluorouracil (5FU) was purchased from MedChemExpress (MCE) Co., Ltd. (Shanghai, China).

    Techniques: In Vitro, Cell Culture, Staining

    In vivo evaluation of chemoresistance in HCC-laden microgels. (A) Macroscopic images of tumors derived from DHCM/GelMA and GelMA microgels after subcutaneous implantation in nude mice followed by 5FU treatment. (B) HE staining of tumors derived from DHCM/GelMA and GelMA microgels post-5FU treatment in subcutaneously implanted nude mice.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: A novel approach for engineering DHCM/GelMA microgels: application in hepatocellular carcinoma cell encapsulation and chemoresistance research

    doi: 10.3389/fbioe.2025.1564543

    Figure Lengend Snippet: In vivo evaluation of chemoresistance in HCC-laden microgels. (A) Macroscopic images of tumors derived from DHCM/GelMA and GelMA microgels after subcutaneous implantation in nude mice followed by 5FU treatment. (B) HE staining of tumors derived from DHCM/GelMA and GelMA microgels post-5FU treatment in subcutaneously implanted nude mice.

    Article Snippet: 5-Fluorouracil (5FU) was purchased from MedChemExpress (MCE) Co., Ltd. (Shanghai, China).

    Techniques: In Vivo, Derivative Assay, Staining

    Evaluation of autophagy activity induced by DHCM. (A) Transmission electron microscopy (TEM) images of Huh7 cells encapsulated in GelMA or DHCM/GelMA hydrogels following 5FU exposure. (B) IF staining of LC3 (green) and AQP3 (red) in Huh7 cells encapsulated in GelMA or DHCM/GelMA hydrogels after 5FU treatment. (C) Quantitative analysis of LC3 IF average optical density (AOD) values in Huh7 cells encapsulated in GelMA or DHCM/GelMA hydrogels following 5FU exposure. (D) Quantitative analysis of AQP3 IF AOD values in Huh7 cells encapsulated in GelMA or DHCM/GelMA hydrogels following 5FU exposure. *p < 0.05, **p < 0.01, and ****p < 0.0001.

    Journal: Frontiers in Bioengineering and Biotechnology

    Article Title: A novel approach for engineering DHCM/GelMA microgels: application in hepatocellular carcinoma cell encapsulation and chemoresistance research

    doi: 10.3389/fbioe.2025.1564543

    Figure Lengend Snippet: Evaluation of autophagy activity induced by DHCM. (A) Transmission electron microscopy (TEM) images of Huh7 cells encapsulated in GelMA or DHCM/GelMA hydrogels following 5FU exposure. (B) IF staining of LC3 (green) and AQP3 (red) in Huh7 cells encapsulated in GelMA or DHCM/GelMA hydrogels after 5FU treatment. (C) Quantitative analysis of LC3 IF average optical density (AOD) values in Huh7 cells encapsulated in GelMA or DHCM/GelMA hydrogels following 5FU exposure. (D) Quantitative analysis of AQP3 IF AOD values in Huh7 cells encapsulated in GelMA or DHCM/GelMA hydrogels following 5FU exposure. *p < 0.05, **p < 0.01, and ****p < 0.0001.

    Article Snippet: 5-Fluorouracil (5FU) was purchased from MedChemExpress (MCE) Co., Ltd. (Shanghai, China).

    Techniques: Activity Assay, Transmission Assay, Electron Microscopy, Staining

    84-EBET shows substantial anticancer efficacy in CRC, LC, and BC models in vitro and in vivo . A, IHC analysis of CRC-1, CRC-5, BRE-704, and H1573 tumors. Scale bar, 100 μm. B, Growth inhibition by ADCs and standard chemotherapies in CRC-1, CRC-5, and BRE-704 PDX-derived organoids and the H1573 cell line. Data are presented as mean ± SD ( n = 4 biological replicates). Fitted curves with nonlinear regression are shown. SN38, an active metabolite of irinotecan. 5FU + OXA has a different concentration range (10 nmol/L to 100 µmol/L + 1 nmol/L to 10 µmol/L) from those of the other agents. C, Relative tumor growth curves in response to ADCs and standard chemotherapies in CRC-1, CRC-5, BRE-704, and H1573 xenograft models. Arrowheads indicate times of drug administration. Data are presented as mean ± SD ( n = 5 mice). CDX, cell line–derived xenograft; HEL, hen-egg lysozyme 3 (control).

    Journal: Molecular Cancer Therapeutics

    Article Title: Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody–Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models

    doi: 10.1158/1535-7163.MCT-24-0444

    Figure Lengend Snippet: 84-EBET shows substantial anticancer efficacy in CRC, LC, and BC models in vitro and in vivo . A, IHC analysis of CRC-1, CRC-5, BRE-704, and H1573 tumors. Scale bar, 100 μm. B, Growth inhibition by ADCs and standard chemotherapies in CRC-1, CRC-5, and BRE-704 PDX-derived organoids and the H1573 cell line. Data are presented as mean ± SD ( n = 4 biological replicates). Fitted curves with nonlinear regression are shown. SN38, an active metabolite of irinotecan. 5FU + OXA has a different concentration range (10 nmol/L to 100 µmol/L + 1 nmol/L to 10 µmol/L) from those of the other agents. C, Relative tumor growth curves in response to ADCs and standard chemotherapies in CRC-1, CRC-5, BRE-704, and H1573 xenograft models. Arrowheads indicate times of drug administration. Data are presented as mean ± SD ( n = 5 mice). CDX, cell line–derived xenograft; HEL, hen-egg lysozyme 3 (control).

    Article Snippet: The chemical materials were purchased from the following suppliers: oxaliplatin (OXA) from Sawai Pharmaceutical; 5-fluorouracil (5FU) from Kyowa Hakko Kirin; fulvestrant (FUL) from AstraZeneca; palbociclib (PAL) from Guiding Bio-Tech; paclitaxel (PTX) from FUJIFILM Wako Pure Chemical Corporation; carboplatin (CBDCA) from Bristol Myers Squibb; DXd from MedChemExpress; and MMAE and SN38 linker payloads from Levena Biopharma.

    Techniques: In Vitro, In Vivo, Inhibition, Derivative Assay, Concentration Assay, Control

    84-EBET modulates CAF gene expression and signaling in a stroma-rich CRC-PDX model. A, RNA-seq analysis of gene expression changes in the stroma of CRC-5 tumors after 5FU + OXA or 84-EBET treatment. Expression fold changes relative to vehicle are represented. Data are presented as mean ± SD ( n = 5 mice). B, Gene set enrichment analysis using upregulated and downregulated stromal genes by 84-EBET treatment is shown. Gene sets: HALLMARK_IL6_JAK_STAT3_SIGNALING, HALLMARK_TGF_BETA_SIGNALING, HALLMARK_INFLAMMATORY_RESPONSE, and HSIAO_HOUSEKEEPING_GENES. Normalized enrichment scores (NES), P -values, and FDR Q -values are shown on the plots.

    Journal: Molecular Cancer Therapeutics

    Article Title: Broad-Spectrum Efficacy of CEACAM6-Targeted Antibody–Drug Conjugate with BET Protein Degrader in Colorectal, Lung, and Breast Cancer Mouse Models

    doi: 10.1158/1535-7163.MCT-24-0444

    Figure Lengend Snippet: 84-EBET modulates CAF gene expression and signaling in a stroma-rich CRC-PDX model. A, RNA-seq analysis of gene expression changes in the stroma of CRC-5 tumors after 5FU + OXA or 84-EBET treatment. Expression fold changes relative to vehicle are represented. Data are presented as mean ± SD ( n = 5 mice). B, Gene set enrichment analysis using upregulated and downregulated stromal genes by 84-EBET treatment is shown. Gene sets: HALLMARK_IL6_JAK_STAT3_SIGNALING, HALLMARK_TGF_BETA_SIGNALING, HALLMARK_INFLAMMATORY_RESPONSE, and HSIAO_HOUSEKEEPING_GENES. Normalized enrichment scores (NES), P -values, and FDR Q -values are shown on the plots.

    Article Snippet: The chemical materials were purchased from the following suppliers: oxaliplatin (OXA) from Sawai Pharmaceutical; 5-fluorouracil (5FU) from Kyowa Hakko Kirin; fulvestrant (FUL) from AstraZeneca; palbociclib (PAL) from Guiding Bio-Tech; paclitaxel (PTX) from FUJIFILM Wako Pure Chemical Corporation; carboplatin (CBDCA) from Bristol Myers Squibb; DXd from MedChemExpress; and MMAE and SN38 linker payloads from Levena Biopharma.

    Techniques: Gene Expression, RNA Sequencing, Expressing